Although the prognostic and treatment implications of APS antibodies and greatly elevated VWF in COVID-19 remain unknown and IgM antibodies are usually not pathogenetic in APS, the authors argued that such unusual laboratory profile suggests a possible role for therapeutic-dose anticoagulation. The gene discussed is VWF; the disease is COVID-19.